MARIETTA, Ga., April 11, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today the nation-wide launch of the Company's latest product, EpiFix™, a biologic implant specifically processed to offer a wide variety of wound healing and wound care options. The Company also announces the hiring of Frank Burrows as its Vice President of Wound Care.
Parker H. "Pete" Petit, Chairman and CEO, stated, "EpiFix™, another of our products resulting from MiMedx Group's proprietary Purion® process, produces an allograft from amniotic tissue which is optimized for numerous wound care applications.. In our clinical studies, EpiFix™ has outperformed the competitive products."
According to the 2010 iData report, the combined U.S. wound and tissue management market was valued to be in excess of $7.4 billion. "With the wound care market representing such a large opportunity, we have added another key executive to our organization. Effective today, Frank Burrows joins MiMedx in the newly created capacity of Vice President of Wound Care. Frank brings to MiMedx over 20 years of experience and expertise in developing and implementing sales and marketing programs that have created growth for numerous medical devices and pharmaceuticals in the areas of wound closure, wound healing, tissue engineering, and bio-active therapeutics. Frank's expertise and in-depth command of the wound care, wound healing and tissue markets was gained through key roles at J & J Wound Management, Smith & Nephew, Advanced Tissue Sciences and Histogen Aesthetics," added Petit.
MiMedx reported that EpiFix™ is the wound care branded tissue resulting from the Company's proprietary Purion® process. The amniotic tissue produced using the Purion® Process has generated a growing demand for
|SOURCE MiMedx Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved